AngioDynamics (NASDAQ:ANGO) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of AngioDynamics (NASDAQ:ANGO) from a hold rating to a buy rating in a report published on Saturday.

A number of other research analysts also recently commented on the company. Zacks Research downgraded AngioDynamics from a “hold” rating to a “strong sell” rating in a research note on Thursday, July 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AngioDynamics in a report on Friday, July 17th. HC Wainwright boosted their price target on AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Finally, Canaccord Genuity Group boosted their price target on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $19.50.

AngioDynamics Stock Performance

Shares of ANGO opened at $15.77 on Friday. The company’s 50 day moving average price is $14.03 and its 200 day moving average price is $12.10. AngioDynamics has a 52 week low of $9.39 and a 52 week high of $16.29. The company has a market capitalization of $651.81 million, a PE ratio of -18.13 and a beta of 0.33.

AngioDynamics (NASDAQ:ANGO) last released its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The company had revenue of $86.61 million during the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. On average, equities analysts forecast that AngioDynamics will post -0.25 earnings per share for the current fiscal year.

Insider Buying and Selling

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 23,370 shares of the business’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total transaction of $344,006.40. Following the completion of the transaction, the senior vice president owned 64,745 shares of the company’s stock, valued at $953,046.40. The trade was a 26.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 6.00% of the stock is owned by company insiders.

Hedge Funds Weigh In On AngioDynamics

A number of institutional investors have recently made changes to their positions in ANGO. Farther Finance Advisors LLC boosted its stake in AngioDynamics by 146.4% during the 4th quarter. Farther Finance Advisors LLC now owns 2,018 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 1,199 shares during the period. Kemnay Advisory Services Inc. bought a new position in AngioDynamics in the 4th quarter worth approximately $27,000. State of Wyoming acquired a new position in shares of AngioDynamics during the second quarter worth approximately $31,000. Legal & General Group Plc acquired a new position in shares of AngioDynamics during the second quarter worth approximately $45,000. Finally, Russell Investments Group Ltd. lifted its holdings in shares of AngioDynamics by 329.5% during the third quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 3,213 shares during the last quarter. 89.43% of the stock is currently owned by institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.